Clinical trialPhase 1
STX-1150 (Tune/CasX epigenetic PCSK9 silencing), first-in-human
NCT07428473
Open-label single-ascending-dose с expansion, план до 64 взрослых с повышенным LDL.
No news refers to this card yet.
Also in the catalogue
- Lp(a)HORIZON (pelacarsen)Clinical trial
- Long-term follow-up of gene-editing recipients (up to 15 years)Clinical trial
- VERVE-102 Heart-2Clinical trial
- CTX310 Phase 1b (secondary identifier NCT07491172)Clinical trial
- ACCLAIM-Lp(a)Clinical trial
- ACCLAIM-CTAClinical trial
Scales
Identifiers
- NCT
- NCT07428473
Original sources
Details
- Phase
- Phase 1
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.